stockrow
Saturday 7 November 2026
Export CADL’s income statement to Excel — free account
Candel Therapeutics, Inc.
CADL Healthcare Biotechnology
Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00.
- EPS
- −477.8%
- Free cash flow
- −93.4%
- Total debt
- +525.8%
Quarter to June 2026, against a year earlier
8.66
0.62
+7.71%
Follow CADL
Alert me
Candel Therapeutics, Inc. (CADL) P/E ratio
Candel Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KURA Kura Oncology, Inc. compare | n/m |
| HELP Cybin Inc. compare | n/m |
| DSGN Design Therapeutics, Inc. compare | n/m |
| DBVT DBV Technologies S.A. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. compare | n/m |
| AVBP ArriVent BioPharma, Inc. compare | n/m |
| GERN Geron Corporation compare | n/m |
| CADL Candel Therapeutics, Inc. | n/m |
| ZVRA Zevra Therapeutics, Inc. compare | 9.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)